

Sheet 1 of 2

FORM PTO 1449 (modified)		Atty. Docket No. X-15558	Serial No. 10/511452
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Applicants Paul Leslie Ornstein	
		Filing Date	Group

U.S. PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Pages or Relevant Figures Appear
<i>AM</i>	AA	5,446,051	August 29, 1995	Ornstein	
	AB	5,356,902	October 18, 1994	Ornstein	
	AC	5,675,008	October 7, 1997	Bertsch, et al.	
	AD	5,670,516	September 23, 1997	Arnold, et al.	
<i>AM</i>	AE	5,767,117	June 16, 1998	Moskovitz	

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ - Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
<i>AM</i>	BA	EP 0 590 789	6 April 1994	Eli Lilly and Company		
<i>AM</i>	BB	WO 01/02367	11 January 2001	Eli Lilly and Company		
	BC	WO 01/01972	11 January 2001	Eli Lilly and Company		
	BD	WO 98/45270	15 October 1998	Eli Lilly and Company		
	BE	WO 01/46173	28 June 2001	Eli Lilly and Company		
	BF	WO 03/024453	27 March 2003	Eli Lilly and Company		
	BG	WO 03/024934	27 March 2003	Eli Lilly and Company		
	BH	WO 02/053555	11 July 2002	Eli Lilly and Company		
<i>AM</i>	BI	WO 02/053556	11 July 2002	Eli Lilly and Company		
<i>AM</i>	BJ	WO 03/082856	9 October 2003	Eli Lilly and Company		

NON PATENT LITERATURE DOCUMENTS


Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s) publisher, city and/or country where published.	T ⁶
<i>AM</i>	CA	Bleakman, et al., "Pharmacological Discrimination of GLUR5 and GLUR6 Kainate Receptor Subtypes by (3S,4AR,6R,8AR)-6-2-(1(2)H-Tetrazole-5-yl)Ethyl Decahydroisoquinoline-3 Carboxylic Acid," Molecular Pharmacology, Baltimore, MD, Vol. 49, No. 4, pgs. 581-585; XP000942899 (1996)	
<i>AM</i>	CB	Buchwald, P. and Bodor, N., Quantitative Structure-Metabolism Relationships: Steric and Nonsteric Effects in the Enzymatic Hydrolysis of noncongener Carboxylic Esters, J. Med. Chem. 42, 5160-5168, 1999.	

AM

2/1/06

Sheet 2 of 2

FORM PTO 1449 (modified)		Atty. Docket No. X-15558	Serial No. 10/511452
INFORMATION DISCLOSURE CITATION IN AN APPLICATION		Applicants Paul Leslie Ornstein	
		Filing Date	Group

	CC	Tanino, T., Ogiso, t., Iwaki, M., Tanabe, G. and Muraoka, O., Enhancement of Oral Bioavailability of Phenytoin by Esterification, and in vitro Hydrolytic Characteristics of Prodrugs, <i>International Journal of Pharmaceutics</i> 163, 91-102, 1998.	
	CD	Shindo, H. Fukuda, K., Kawai, K. and Tanaka, K., Studies on Intestinal Absorption of Pivampicillin and Species Difference in the Intestinal Esterase Activity, <i>J. Pharm. Dyn.</i> 1, 310-323, 1978.	
	CE	O'Neill, MJ, et al., "Decahydroisoquinolines: Novel competitive AMPA/kainite antagonists with neuroprotective effects in global cerebral ischaemia," <i>Neuropharmacology</i> , 37, pgs. 1211-1222 (1998)	
	CF	Sahara, Y, et al., "Glutamate receptor subunits GluR5 and KA-2 are coexpressed in rat trigeminal ganglion neurons," <i>The Journal of Neuroscience</i> , 17(17), pgs. 6611-6620 (1997)	
	CG	Alam, Z., et al., "Plasma levels of neuroexcitatory amino acids in patients with migraine or tension headache," <i>Journal of Neurological Sciences</i> , 156, pgs. 102-106 (1998)	
	CH	Ornstein, et al., "Structure-Activity Studies of 6-Substituted Decahydroisoquinoline-3-carboxylic Acid AMPA Receptor Antagonists. 2. Effects of Distal Acid Bioisosteric Substitution, Absolute Stereochemical Preferences, and in Vivo Activity, <i>J. Med. Chem.</i> , Vol. 39, No. 11, pgs. 2232-2244 (1996)	
	CI	Procter, et al., "Possible role of GluR5 glutamate receptors in spinal nociceptive processing in the anaesthetized rat," <i>Journal of Physiology</i> , XX, XX, Vol. 405P, pgs. 101P-102P; XP002108296 (1997)	
	CJ	Nakam, et al., "The search for AMPA/Gly(N) receptor antagonists," <i>Drugs Future</i> , Vol. 24, No. 10, pgs. 1107-1124; XP000997758 (1999)	
	CK	Procter, et al., "Actions of kainite and AMPA selective glutamate receptor ligands on nociceptive processing in the spinal cord," <i>Neuropharmacology</i> , Oct. - Nov., 1998, 37 (10-11), pgs. 1287-1297; XP000997628 (1998)	
	CL	Bleakman, "Kainate receptor pharmacology and physiology," <i>Cellular and Molecular Life Sciences</i> , 56/7-8 (558-566); XP000990931	
	CM	Simmons, et al., "Kainate GluR5 receptor subtype mediates the nociceptive response to formalin in the rat," <i>Neuropharmacology</i> , 37(1), pgs 25-36; XP000997629 (1998)	
	CN	Database Medline "Online", US National Library of Medicine (NLM), Bethesda, MD, US; Mitsikostas D.D., et al, "Non-NMDA glutamate receptors modulate capsaicin induced c-fos expression within trigeminal nucleus caudalis," retrieved from DIALOG, Database accession no. 10003939; XP002165715 abstract & British <i>Journal of Pharmacology</i> , June, 1999 (127 (3)); pgs. 623-630	
Examiner Signature		Date Considered	2/11/2005

¹EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

²Applicant's unique citation designation number (optional). ³See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ⁴Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁵For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁶Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁷Applicant is to place a check mark here if English language Translation is attached. Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.